Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial
- 15 November 2007
- Vol. 335 (7630) , 1139
- https://doi.org/10.1136/bmj.39381.436829.be
Abstract
Objective To investigate the feasibility of testing for prostate cancer and the prevalence and characteristics of the disease in unselected young men.Design Prospective cohort nested within a randomised controlled trial, with two years of follow-up.Setting Eight general practices in a UK city.Participants 1299 unselected men aged 45-49.Intervention Prostate biopsies for participants with a prostate specific antigen level of 1.5 ng/ml or more and the possibility of randomisation to three treatments for those with localised prostate cancer.Main outcome measures Uptake of testing for prostate specific antigen; positive predictive value of prostate specific antigen; and prevalence of prostate cancer, TNM disease stage, and histological grade (Gleason score).Results 442 of 1299 men agreed to be tested for prostate specific antigen (34%) and 54 (12%) had a raised level. The positive predictive value for prostate specific antigen was 21.3%. Ten cases of prostate cancer were detected (2.3%) with eight having at least two positive results in biopsy cores and three showing perineural invasion. One tumour was of high volume (cT2c), Gleason score 7, with a positive result on digital rectal examination; nine tumours were cT1c, Gleason score 6, and eight had a negative result on digital rectal examination. Five of the nine eligible participants (55%) agreed to be randomised. No biochemical disease progression in the form of a rising prostate specific antigen level occurred in two years of follow-up.Conclusions Men younger than 50 will accept testing for prostate cancer but at a much lower rate than older men. Using an age based threshold of 1.5 ng/ml, the prevalence of prostate cancer was similar to that in older men (3.0 ng/ml threshold) and some cancers of potential clinical significance were found.Trial registration Current Controlled Trials ISRCTN20141297Keywords
This publication has 24 references indexed in Scilit:
- Pathological Characteristics of Prostate Cancer Detected Through Prostate Specific Antigen Based ScreeningJournal of Urology, 2006
- PROSTATE SPECIFIC ANTIGEN LEVELS IN YOUNG ADULTHOOD PREDICT PROSTATE CANCER RISK: RESULTS FROM A COHORT OF BLACK AND WHITE AMERICANSJournal of Urology, 2005
- Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per MilliliterNew England Journal of Medicine, 2004
- Prostate Testing for Cancer and Treatment (ProtecT) feasibility studyHealth Technology Assessment, 2003
- Screening for prostate cancer in high risk populations.Published by Rockefeller University Press ,2002
- Quality improvement report Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study Commentary: presenting unbiased information to patients can be difficultBMJ, 2002
- A placebo-controlled randomized trial of eradication of Helicobacter pylori in the general population:Controlled Clinical Trials, 2002
- PROSTATE CANCER IN MEN AGE 50 YEARS OR YOUNGER:: A REVIEW OF THE DEPARTMENT OF DEFENSE CENTER FOR PROSTATE DISEASE RESEARCH MULTICENTER PROSTATE CANCER DATABASEJournal of Urology, 2000
- Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.JAMA, 2000
- Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: Results of a large screening studyUrology, 1995